|
BioForce Nanosciences to Collaborate With University Pierre & Marie
Curie
AMES, IA, Nov 13, 2008 (MARKET WIRE via COMTEX) --
BioForce Nanosciences Holdings, Inc. (OTCBB: BFNH), a leader in
systems integration at the micro- and nano-scales to create products
for the life sciences, is pleased to announce that it has signed a
scientific collaboration agreement with the University Pierre & Marie
Curie (UPMC) and CNRS (Centre National de Recheche Scientifique) in
Paris, France. Under the terms of this agreement, researchers from
the laboratory of Dr. Fatiha Nothias will collaborate with BioForce to
develop technologies, protocols, and products related to neural
cell-based assays.
These proprietary assays will be created using the Nano eNabler(TM)
molecular printer from BioForce, and they will allow scientists to
study the structure, function, and microenvironments of neural cells.
In particular, neural cell-based assays hold great promise as a
platform for evaluating the therapeutic potential of new drug
compounds and treatments for neurodegenerative diseases and neural
trauma.
Dr. Fatiha Nothias, Principal Investigator at UPMC, said, "This novel
molecular micro-printing device appears to be a very useful and
flexible technology to bring new insights into the cellular response
processes, such as proliferation, apoptosis, morphogenesis, and
differentiation. In particular, we are focusing on axonal outgrowth
in the nervous system, which is controlled by specific extracellular
cues that exhibit a precise spatial and temporal distribution,
allowing the axon to reach its target. Mimicking in vitro, at least
partially, the in vivo environment, is a big challenge. Thus it is a
great opportunity for us to collaborate with BioForce. We are very
enthusiastic in using the Nano eNabler system to investigate how
growth cones (highly motile distal tip of the neuronal axon) are
sensing and are influenced by micropatterned substrates."
BioForce's Product Manager, Michael Lynch, said, "We have enjoyed
working closely with Dr. Nothias and the UMPC over the past two years
as they have pushed the capabilities of our Nano eNabler technology.
This collaborative agreement emphasizes our continued interest in
supporting cutting edge applications and bringing them to the market
as novel products. The biomedical research community has made
fantastic advances in a number of areas, however, there are still a
great many unknowns in brain research, and deciphering that
complexity represents a massive international effort and opportunity.
As an example, there are nearly 40,000 members of the Society for
Neuroscience working around the globe to unravel the mysteries of the
human brain. We believe that our products are the type of tools that
these researchers need in order to unlock the mysteries of the human
brain, and develop therapies that more effectively treat neural
disorders."
On November 18, Dr. Fatiha Nothias will be presenting her most recent
results at the Society for Neuroscience 2008 conference in
Washington, DC. The title of her talk is "Micropatterned Adhesive
Extracellular Matrix Substrates Reveal Specific Response of DRG
Neuron Growth Cone." BioForce Nanosciences will also be presenting a
research poster at the same conference, titled, "Basolateral
Activation of Neural Crest-Derived PC-12 Cells." An electronic copy
of this poster may be downloaded from the BioForce Resources Library
after it has been presented. Representatives from BioForce will be
available in the Society for Neuroscience exhibit hall at booth
#1206.
BioForce Nanosciences will also be exhibiting at TERMIS 2008 (Tissue
Engineering & Regenerative Medicine International Society) in San
Diego, CA on December 7-10, and the American Society for Cell Biology
in San Francisco, CA on December 13-17.
For further information about this release please contact Greg Brown,
Chief Financial Officer of BioForce at (515) 233-8333 ext. 118, or
Rich Kaiser, Investor Relations at (800) 631-8127.
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences creates products and solutions for the life
sciences by integrating biological and mechanical systems at the micro
and nano scales. BioForce's flagship product, the Nano eNabler(TM)
molecular printer, gives the Company and its customers a platform for
development and discovery by printing tiny domains of biological
materials on surfaces with nanometer spatial precision. BioForce
technology is being used in areas such as biosensor
functionalization; patterning and cell adhesion; and the printing of
proteins to guide neural cell growth. For more information, visit
www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be
affected by certain risks and uncertainties, including those risks and
uncertainties described in BioForce Nanosciences' most recent filings
with the Securities and Exchange Commission. BioForce Nanosciences'
actual results could differ materially from such forward-looking
statements. BioForce assumes no duty to update these statements at
any future date.
Contacts:
Company Contact
Gregory D. Brown
Chief Financial Officer
515-233-8333 ext# 118
Email Contact
Investor Relations
Yes International
Rich Kaiser
800-631-8127
SOURCE: BioForce Nanosciences Holdings, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=B473D29A77B82D8D
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
